General description

Recombinant, human αA-interferon expressed in E. coli. Antiviral, anti-neoplastic agent. αA-Interferon exhibits therapeutic potential with chronic viral hepatitis, polycythemia vera, and various malignancies. It enhances natural killer cell activity, suppresses bone marrow function, and induces apoptotic cell death in non-melanoma skin cancer. NOTE: 1MU = 1,000,000 units.

Note: 1 MU = 1,000,000 units.

Recombinant, human αA-interferon expressed in E. coli. Antiviral, anti-neoplastic agent. αA-Interferon exhibits therapeutic potential in chronic viral hepatitis, polycythemia vera, and various malignancies. It enhances natural killer cell activity, suppresses bone marrow function, and induces apoptotic cell death in non-melanoma skin cancer.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Fujishima, H., et al. 1998. Int. J. Cancer 76, 423.Haria, M., and Benfield, P. 1995. Drugs 50, 873.Familletti, P.C., et al. 1981. Methods Enzymol. 78, 387.

Packaging

5 mu in Plastic ampoule

Physical form

In PBS containing 0.1% BSA.

Preparation Note

Dilute only in buffers containing protein such as 0.1% BSA.

Reconstitution

Following initial thaw, aliquot and freeze (-70°C).

Unit Definition

One unit of interferon per ml of medium will cause a 50% inhibition of VSV-induced cytopathic effect on bovine MDBK cells. Units are determined with respect to the NIH international reference standard for human αA-IFN. Dilute in aqueous buffer containing at least 0.1% BSA or HSA.

Warning

Toxicity: Standard Handling (A)